Alnylam Announces New RNAi Therapeutic Program for the Treatment of Hepatitis B Virus (HBV) Infection and Reports an Up to 2.3 Log10 Reduction of HBV Surface Antigen (HBsAg) in Chronically Infected Chimpanzees

[Business Wire] – Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that it has named a new program to its pipeline: ALN-HBV for the treatment of hepatitis B virus infection. more

View todays social media effects on ALNY

View the latest stocks trending across Twitter. Click to view dashboard

See who Alnylam is hiring next, click here to view